Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke.
2010 (English)In: Stroke, ISSN 0039-2499, E-ISSN 1524-4628, Vol. 41, no 2, 397-401 p.Article in journal (Refereed) Published
BACKGROUND AND PURPOSE: To prevent new cardiovascular events after stroke, prescribed preventive drugs should be used continuously. This study measures persistent use of preventive drugs after stroke and identifies factors associated with persistence.
METHODS: A 1-year cohort (21,077 survivors) from Riks-Stroke, the Swedish Stroke Register, was linked to the Swedish Prescribed Drug Register.
RESULTS: The proportion of patients who were persistent users of drugs prescribed at discharge from hospital declined progressively over the first 2 years to reach 74.2% for antihypertensive drugs, 56.1% for statins, 63.7% for antiplatelet drugs, and 45.0% for warfarin. For most drugs, advanced age, comorbidity, good self-perceived health, absence of low mood, acute treatment in a stroke unit, and institutional living at follow-up were independently associated with persistent medication use.
CONCLUSIONS: Persistent secondary prevention treatment declines rapidly during the first 2 years after stroke, particularly for statins and warfarin. Effective interventions to improve persistent secondary prevention after stroke need to be developed.
Place, publisher, year, edition, pages
American Heart Association , 2010. Vol. 41, no 2, 397-401 p.
medication persistence, secondary prevention, stroke
Social and Clinical Pharmacy
IdentifiersURN: urn:nbn:se:umu:diva-35680DOI: 10.1161/STROKEAHA.109.566950PubMedID: 20075360OAI: oai:DiVA.org:umu-35680DiVA: diva2:346176